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Modified multiple drug resistance phenotype of Chinese hamster ovary
cells selected with X-rays and vincristine versus X-rays only
S. McClean' & B.T. Hill2
Cellular Chemotherapy Laboratory, Imperial Cancer Research Fund, PO Box 123, Lincoln's Inn Fields, London WC2A 3PX, UK.
Summary Exposure of Chinese hamster ovary (CHO) cells to fractionated X-irradiation [ten fractions of 9
Gray (Gy)] resulted in the expression of a multiple drug resistance phenotype which was distinct from that of
drug-selected cells in two features: (i) resistance to vinca alkaloids and epipodophyllotoxins but sensitivity to
anthracyclines was retained; (ii) overexpression of P-glycoprotein (Pgp) but regulated by post-translational
stability rather than by any elevation in Pgp mRNA (Hill et al., 1990). It was also reported that when these
cells (designated DXR-10) were subsequently exposed to another ten fractions of9 Gy (20 x 9 Gy in total), no
further increases in drug resistance or in the extent of Pgp expression were observed. To examine this apparent
plateauing of the drug resistance phenotype following X-ray pretreatment, DXR-10 cells were instead treated
with ten pulsed vincristine exposures. The resultant cell line, designated DXR-10/VCR-10, proved to be more
resistant to vincristine, implying that the effect of further drug selection was additive to that of X-ray
pretreatment. In addition, these cells showed resistance to doxorubicin and increased Pgp expression which
was matched by a concomitant elevation in Pgp mRNA. These findings appear to confirm that Pgp expression
is differentially regulated in tumour cells showing drug resistance after drug as opposed to X-ray selection.
Resistance to multiple anti-tumour agents has been encoun-
tered not only in patients who have received drug treatment;
certain patients who have been treated with radiotherapy
have also been found to be resistant to multiple drugs (Hill,
1991). Previous in vitro studies from this laboratory have
indicated that the basis of this phenomenon may be biolo-
gical (Hill et al., 1990; McClean et al., 1993a). In particular,
tumour cells exposed to several fractions of X-rays in vitro
expressed a stable multiple drug-resistant phenotype that was
characterised by resistance to vinca alkaloids and epipodo-
phyllotoxins but not to anthracyclines and overexpression of
P-glycoprotein (Pgp) in the absence of any elevation in Pgp
mRNA expression. Two distinct features of this phenotype
contrast with that observed in drug-selected classical multiple
drug-resistant cells which generally show (i) resistance to
anthracyclines as well as to the vinca alkaloids and epipodo-
phyllotoxins, and (ii) concomitant elevations in Pgp mRNA
and/or gene amplification with Pgp overexpression (Cordon-
Cardo & O'Brien, 1991; Biedler, 1992).
The original report (Hill et al., 1990) that outlined the
characterisation of X-ray-pretreated Chinese hamster ovary
(CHO) cells demonstrated a further distinctive feature of this
phenotype. In general, when a series of sublines have been
selected for drug resistance by increasing the concentration of
the selecting agent, such as colchicine (COL) or vincristine
(VCR), the levels of resistance to the selecting agent and to
other drugs increase incrementally (e.g. Shen et al., 1986;
Bradley et al., 1989). More recently, it has been shown that
increased numbers ofpulsed, as opposed to continuous, drug
exposures can also result in an increase in the level of drug
resistance. For example, two MCF-7 sublines derived using
pulsed exposures to VCR (Whelan & Hill, 1993) proved
increasingly resistant to VCR and cross-resistant to etoposide
(VP-16) and to doxorubicin (DOX) and overexpressed Pgp to
a greater degree when the number ofexposures was increased
from three to six. In addition, when parental AuxBl CHO
cells which had received five fractions of 9 Gray (Gy), desig-
nated DXR-5, were exposed to a further five fractions, result-
ing in a DXR-10 subline, levels of resistance to VCR and to
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VP-16 increased, together with the degree of Pgp overexpres-
sion (Hill et al., 1990). However, when DXR-10 cells were
subsequently exposed to a further ten fractions of 9 Gy (total
dose of 20 x 9 Gy), the resulting subline, designated DXR-
20, did not show any further increase in levels of resistance
to VCR, vinblastine (VBL) or to VP-16 and there was no
further enhancement ofPgp overexpression (Hill et al., 1990).
To examine this apparent plateauing of resistance follow-
ing further X-irradiation treatment, DXR-10 cells were trea-
ted with ten pulsed exposures ofVCR. Pulsed exposures were
chosen, as opposed to continuous drug exposure, since they
were considered more comparable with the fractionated X-
ray pretreatments. This newly derived subline, designated
DXR-10/VCR-10, was then studied in terms of resistance
patterns, ability to efflux rhodamine 123 (Rh123) and Pgp
content, stability and mRNA expression. Characterisation of
this cell line has confirmed that different mechanisms of Pgp
regulation exist in X-ray-pretreated sublines relative to that
identified after selection with either drug alone or drug fol-
lowing X-rays.
Methods
Anti-tumour agents
VCR and DOX were donated for these studies by Lederle
Laboratories (Gosport, Hants, UK) and by Farmitalia Carlo
Erba (Milan, Italy) respectively. COL and verapamil (VRP)
were purchased from Sigma (Poole, UK).
Derivation ofthe subline
In order to be strictly comparable with the schedule of X-ray
exposures previously adopted (Hill et al., 1990), DXR-10
cells should have received ten VCR pulses at a concentration
which resulted in two logs ofcell kill. However, since VCR is
a class II agent, according to the kinetic classification of
anti-tumour drugs (Bruce et al., 1966), the survival curve for
AuxBl cells exposed to a range of VCR concentrations for
24 h generally plateaued at a concentration of 100 ng ml '
when approximately 1 log cell kill was achieved. Therefore,
selecting one of the two independently derived DXR-10 sub-
lines (Hill et al., 1990), namely line DXR-1OII, the cells were
treated with ten pulsed 24 h exposures of 00 ngml-' VCR
over a period of 14 weeks, with the population being permitted
to return to logarithmic growth in between each treatment,
and the resultant subline was designated DXR-10/VCR-10.
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All cell lines used in this study, AuxBl, DXR-10I, DXR-
1OII, DXR-10/VCR-10 and CHRC5, were maintained in
modified essential medium a (MEM-a) plus 10% fetal calf
serum (FCS) (Gibco Life Technologies, Perth, UK).
Characterisation ofthe subline
The responses of the DXR-10/VCR-10 subline to anti-
tumour agents were determined by treating logarithmically
growing cells with a range of drug concentrations in dup-
licate for 24 h prior to harvesting with trypsin. The cells were
then plated into MEM-c plus 10% FCS with 0.17% agarose
(Flowgen Instruments, Sittingbourne, Kent, UK). Colonies
were counted following 14 days' incubation at 37°C. Dose-
response curves were drawn, from which IC5o values were
calculated as the concentration of drug required to reduce
cell survival to 50% of non-drug-treated controls.
For estimations of protein and DNA content, cells were
counted using a haemocytometer. Protein content and DNA
levels were assayed by published methods (Burton, 1956;
Bradford, 1976). Cell volumes were determined using a
Coulter Counter (model ZM) (Coulter Electronics, Luton,
UK).
Expression ofP-glycoprotein and Pgp mRNA
Membrane fractions were prepared from the CHO cells by
the method of Bradley et al. (1989) using a series of centri-
fugation steps. Pgp levels were analysed by Western blotting
using C219 (Centocor, CIS UK, High Wycombe, Bucks,
UK) or C494 (kindly donated by V. Ling, Ontario Cancer
Institute, Toronto, Canada) monoclonal antibodies based on
the method of Kartner et al. (1985). Northern analysis of
poly(A)+ RNA was carried out according to the procedure
of Bradley et al. (1988). Aliquots of 2 or 4yg of poly(A)+
RNA were separated on 1% agarose-formaldehyde gels and
transferred to Zetabind nylon membranes (Biorad Laborator-
ies, Milton Keynes, Hertfordshire, UK) according to publish-
ed methods (Sambrook et al., 1989) and probed sequentially
with the CHO cDNA probe pCHPI (Riordan et al., 1985)
and a cDNA for glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (Tso et al., 1985), used to correct for any di-
fferences in poly(A)+ RNA loading on the gels. The cDNA
probes were labelled with [32P]dATP (Amersham Interna-
tional, Amersham, UK) using the Megaprime kit (Amer-
sham) and the hybridisation protocol followed was that of
Church and Gilbert (1984).
Rh123 efflux
Examination of Rhl23 efflux was carried out according to
the method of Ludescher et al. (1992). Cells (107) were
preloaded with 200 ngml-' Rh123 for 45 min, washed twice
with ice-cold PBS and efflux of Rhl23 was monitored at
room temperature by flow cytometry over a 60min period in
the presence or absence of 6.6zlM VRP. Fluorescence inten-
sity was detected using a FACScan (Becton Dickinson, Ply-
mouth, UK) through a 520/530 nm bandpass filter and ex-
pressed as the mean fluorescence of5,000 cells gated by forward
and 900 scattered light, in order to measure viable cells only.
Determination ofPgp half-life in DXR-JO/VCR-10 cells
Logarithmically growing cells were preincubated in methio-
nine-free (met-) medium plus 10% dialysed FCS (dFCS) for
2 h. The medium was then replaced with met- medium plus
10% dFCS containing 20 liCi ml-' [35S]methionine (Amer-
sham) and the cells were metabolically labelled for 18 h. Cells
were washed four times with phosphate-buffered saline (PBS)
before addition of MEM-a plus 10% FCS. For the 'zero
time' samples, cells were harvested immediately after wash-
ing, while the remaining flasks were incubated at 37°C for
periods of up to 44h. Pgp was immunoprecipitated with
C219 according to the method of Anderson and Blobel
(1983). Briefly, cell lysates were incubated with C219 (10 sg
ml-' overnight at 4°C) and supernatants incubated with
preconditioned protein A-Sepharose beads (Pharmacia LKB
Biotechnology, Uppsala, Sweden) for 2 h. Following washing
with 0.03% SDS, 0.1% Triton-X 100, 150mM sodium chlo-
ride, 5 mg ml' bovine serum albumin, in 0.05M Tris-HCl
containing protease inhibitors, the immunoprecipitated pro-
teins were eluted from the protein A-Sepharose beads with
sample buffer [4% sodium dodecyl sulphate (SDS), 20%
glycerol, 10% mercaptoethanol, in 0.05 M Tris-HCl, pH 7.0],
and analysed by SDS-PAGE according to the method of
Fairbanks et al. (1971). The gels were fixed, dried under a
vacuum and the "S-labelled proteins monitored by fluoro-
graphy. Levels of radiolabelled Pgp were determined by
densitometry of autoradiographs using an LKB laser den-
sitometer, with an LKB software package as described prev-
iously (McClean & Hill, 1993a).
Statistical analysis
The significance of the resistance indices was determined by
Student's t-test, comparing the IC50 values derived for each
cell line from full dose-response curves with respect to the
drug being studied.
Results
Cell line characterisation
The DXR-10/VCR-10 cell line was derived by treating DXR-
1011 cells with ten 24 h pulses of VCR (100 ngml'). Their
population doubling time (20 ± 1 h), protein content (218 +
38 fig 10-6 cells), DNA level (6.8 ± 0.1 fig 10-6 cells) and cell
volume (1173 ± 30gsm3) proved to be similar to those of the
DXR-10II cells (McClean et al., 1993b).
Response ofDXRJO/VCRIO cells to anti-tumour agents
Colony-forming assays following 24 h exposures to VCR
revealed that DXR-10/VCR-10 cells proved significantly (P
<0.01) more resistant to VCR than DXR-1OII cells (Figure
1, Table I), showing that levels ofresistance in the DXR-1OII
cells can be elevated by further drug selection, contrasting
with the lack of effect of ten further X-ray exposures on the
level of drug resistance expressed by the DXR-20 cells (Hill
et al., 1990). In addition, following this further drug select-
ion, these DXR-I0/VCR-10 cells showed significant resistance
(P<0.01) to DOX (Figure lb, Table I), again contrasting
with the DXR-10 and DXR-20 cells.
Expression ofP-glycoprotein andPgp mRNA
The results of Western blotting using the C219 and C494
monoclonal antibodies are shown in Figure 2. DXR-10/
VCR-10 cells expressed a 2- to 3-fold higher level of Pgp
relative to DXR-10II cells as determined by comparative
densitometry readings (Table I). This increase appears to
correlate with the enhanced resistance and, again, indicates
that VCR selection is additive to the initial effects of frac-
tionated X-ray exposure in the development of increasing
drug resistance in these DXR-10/VCR-10 cells. Relative
levels of Pgp mRNA were determined by Northern blotting
using pCHPl cDNA (Figure 3). The DXR-10/VCR-10 cells
expressed elevated levels ofPgp mRNA relative to the DXR-
1OII and DXR-IOI cells (Figure 3), consistent with their
increased level of Pgp expression, shown by comparative
densitometry to be 6- and 8-fold elevated relative to levels
detected in the DXR-10I and AuxBI cells respectively (Table
I).
Rh123 efflux
Efflux of Rh123 from the DXR-I0/VCR-10 cells was deter-
mined by flow cytometry over a 60 min period (Figure 4).
The AuxBl cells showed some efflux of Rhl23 (approx-MULTIPLE DRUG RESISTANCE PHENOTYPES 713
Table I Summary of altered characteristics of the DXR-I0/VCR-10 cells relative to AuxBl cells and
DXR-1OII cells
AuxBl DXR-IOII DXR/VCR-JO
Resistance indexa to
VCR 1.0 (l5 ng ml)b 3.8c 6.0c,d
ADR 1.0 (II ngml-l)b 1.3 2.4de
Pgp overexpressionf
C219 1.0 6.1 0.9 12.1 1.0
C494 1.0 2.7±0.2 7.1±0.4
Relative mRNA expression" 1.00 1.35 ± 0.1 8.00
Pgp half-life ND 40 h 20 h
Rh123 remaining after 15 min efflux (%)
- VRP 78±9 37±4 20±1
+ VRP (6.6jM) 100 1 95 1 98 1
Results represent the means ± s.e.m. aResistance index: ratio of mean ICo values of drug-resistant
subline relative to that of AuxBl cells.bIC5o values for AuxBl cells, i.e. the drug concentration required
to reduce cell survival to 50% of untreated control. cStatistically different from AuxBl cells, P<0.01.
dStatistically different from DXR-OII cells, P<0.01. eStatistically different from AuxBl cells, P<0.05.
'As determined by comparative densitometry of Western blots. gAs determined by comparative
densitometry of Northern blots. ND, not determined.
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Figure 1 Response of AuxBl (-), DXR-1011 (A) and DXR-I0/
VCR-10O (v) cells to a 24 h exposure of(a) VCR and (b) DOX as
determined by colony-forming assay. The results represent the
means ± s.e.m. of two experiments.
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Figure 2 Expression of Pgp in differentially selected CHO sub-
lines by Western blotting. Crude membrane fractions (50fg pro-
tein per lane) were separated by SDS-PAGE, transferred to
nitrocellulose and probed with either (a) C219 or (b) C494 and
'251-labelled anti-mouse IgG. CHRC5 cells were used as a positive
control for Pgp expression. (The lane labelled VRP/DXR-10
refers to another newly developed subline, details ofwhich will be
published elsewhere, not relevant to this paper.)714 S. McCLEAN & B.T. HILL
imately 25%) over the first 60 min, while the DXR-1OII cells
effluxed 60% in the first 15 min. The DXR-10/VCR-10 cells
showed a very rapid efflux of RhI23, with 80% being
removed from the cells in 15 min. This faster efflux of Rhl23,
relative to the DXR-IOII cells, was consistent with their
higher level ofPgp expression. VRP inhibited efflux of Rhl23
in all sublines, as demonstrated by the percentage fluores-
cence remaining in the cells after 15 min in the presence of
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VRP (Table I), consistent with Pgp-mediated efflux of intra-
cellular fluorescence.
Turnover ofPgp in the DXR-IO/VCR-JO cells
Since Pgp mRNA increased concomitantly with Pgp overex-
pression in the DXR-10/VCR-10 cells, Pgp turnover was
examined in the DXR-10/VCR-10 cells to investigate whether
it occurred at a rate similar to that in other drug-selected
CHO cell lines or with the slower half-life observed in DXR-
10II cells (McClean et al., 1993b). Densitometry of resultant
autoradiographs (see Figure 5) revealed that levels of Pgp in
DXR-10/VCR-10 cells were reduced to 50% within approx-
imately 20 h, clearly closer to the range observed for the two
COL-selected CHO sublines (12 and 17 h) than that noted in
the DXR-1OII cell Line (>40h) (McClean et al., 1993b).
Discussion
In the original report (Hill et al., 1990) showing that when
AuxBl cells are exposed to 20 as opposed to ten fractions of
X-rays resistance to VCR, COL and VP-16 does not increase
concomitantly and Pgp expression is not further enhanced it
was suggested that the level of resistance expressed had an
upper threshold in these irradiated (DXR-10) cells. This
finding contrasts with the more general observation in MDR
drug-selective tumour cells: increased resistance to drugs and
associated elevations in Pgp and Pgp mRNA occur with
increasing selection pressure (Shen et al., 1986; Bradley et al.,
1989). We have now shown that when CHO/DXR-10 cells
Time (h)
M 0 8 18 40 C5
Figure 3 Expression of Pgp mRNA in differentially derived
CHO sublines determined by Northern analysis of poly(A)+
RNA (2 or 41g per lane) prepared from CHO sublines and
probed with pCHPI and GAPDH cDNA probes. CHRC5 cells
were used as a positive control.
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Figure 4 Efflux of Rhl23 from CHO sublines (0, AuxBI; A,
DXR-10II; V, DXR-I0/VCR-10). Cells were preloaded with
Rh123 following a 45 min incubation with 200 ngml' Rhl23 at
room temperature. Cells were washed and Rhl23 efflux was
followed over a 60 min period by flow cytometry. The graph
represents the mean ± s.e.m. of two experiments.
Figure 5 Turnover of Pgp in DXR-IO/VCR-10 cells as deter-
mined by immunoprecipitation of 35S-labelled Pgp with C219
monoclonal antibody at different times. Results of two indepen-
dent experiments are shown as a and b. C4, CHRC5 cells used as
a positive control for Pgp expression; M, molecular weight
markers in kDa.
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receive ten pulsed exposures to VCR they become more
resistant to VCR and their overexpression of Pgp is in-
creased. Furthermore, the increased ability of these DXR-10/
VCR-10 cells to efflux Rhl23 confirms that there is an in-
crease in functional Pgp expression. The work outlined in
this report, therefore, demonstrates that the apparent plateau
in drug resistance can be overcome by drug selection but not,
as previously reported (Hill et al., 1990), by further X-ray
selection.
Certain features of the phenotype associated with the
DXR-1OII cells are altered as a result of their further drug
selection. These DXR-10/VCR-10 cells proved to be resistant
to DOX, suggesting that the Pgp specificity of these cells is
similar to that of other drug-selected resistant cells (Shen et
al., 1986; Bradley et al., 1989), rather than showing the
distinctive drug resistance profile of the DXR-10 cells (Hill et
al., 1990). The lack of DOX resistance is a characteristic not
only of CHO cells that have been exposed to prior X-
irradiation (Hill et al., 1990), but also of human tumour
sublines pretreated with seven courses of X-irradiation (Hill,
1991), which similarly express a multiple drug resistance
phenotype. The development of DOX resistance in these
DXR-10/VCR-10 cells therefore implies that the drug resis-
tance phenotype that was induced in these cells following
drug selection is modified from that shown following X-ray
pretreatments. One possible explanation for this may be that
the Pgp that is overexpressed following X-ray pretreatment,
although recognised by both C219 and C494 monoclonal
antibodies (McClean & Hill, 1993a), differs from the Pgp that
is overexpressed following drug selection and exhibits an
altered substrate recognition profile. Choi et al. (1988) ob-
served that mutations in the MDR] sequence which occurred
during COL selection of a KB subline resulted in an amino
acid change (glycine 185 to valine 185). These KB-8-5-11-24
cells that expressed this mutated Pgp showed preferential
resistance to COL over other drugs such as DOX and VBL
(Choi et al., 1988). In agreement with this, independent
studies have shown that single amino acid substitutions intro-
duced into cells in the eleventh or sixth transmembrane
domain of Pgp alter its substrate specificity (Gros et al.,
1991; Devine et al., 1992). These altered Pgps confer cross-
resistance patterns significantly different from those conferred
by the non-mutated protein (Gros et al., 1991; Devine et al.,
1992). These findings indicated that the Pgp sequence can
determine the pattern ofcross-resistance expressed. However,
it can be predicted that the frequency of point mutations
following a 9 Gy X-ray dose would be of the order of 10'
per cell (Thacker, 1992). Therefore, because of the manner in
which the DXR-10 cells were derived, with the AuxBl cells
receiving X-ray doses resulting in only a two log cell kill per
fraction, and the fact that the surviving population was not
cloned (Hill et al., 1990), it is unlikely that single amino acid
mutations resulted in Pgp overexpresion throughout the
DXR-10 cell population. Nevertheless, it is possible that any
alteration in Pgp, including qualitative changes in glycosyla-
tion or phosphorylation or even in subcellular distribution,
might modulate the ability of Pgp to transport ADR. Future
studies will aim to examine these possibilities.
Expression of Pgp in the CHO/DXR-10 cells was assoc-
iated with a post-translational increase in Pgp stability,
rather than with any elevation of Pgp mRNA (McClean et
al., 1993a), a finding also observed in an X-ray-pretreated
human ovarian tumour cell line (McClean & Hill, 1993b).
Comparative densitometry of Northern blots revealed that
Pgp expression in the DXR-10/VCR-10 cells was associated
with a 6-fold increase in Pgp mRNA, suggesting that Pgp
expression was regulated by transcriptional regulation in
drug-selected cells, contrasting with post-translational regula-
tion in cells selected with X-irradiation only. The half-life of
Pgp in these DXR-10/VCR-10 cells was found to be 20h,
which was similar to that of the drug-selected CHO sublines
rather than that observed in the DXR-IOII cells, from which
this subline was derived. This appears to confirm that regula-
tion of Pgp expression differs in resistant cells which have
been selected with X-rays only, as opposed to those selected
with cytotoxic drugs alone or with drugs following X-ray
selection.
The precise mechanism(s) involved in the expression of
multiple drug resistance following X-ray selection remain to
be established. One possibility suggested by the data present-
ed here is that irradiation damages some component involved
in the turnover of Pgp. Subsequent further selection with
X-irradiation has no further effect since the damage occurred
during the initial selection. If this were the case, subsequent
selection with VCR would result in increased transcription of
pgpl together with an extended half-life of Pgp. Since the
half-life of Pgp in DXR-10/VCR cells is only 20 h, it appears
that the mechanisms involved are rather more complex. It is
also interesting to note that Pgp expressed in cells that
showed resistance to DOX had a half-life of 12-20 h, while
the DXR-10 cells, in which Pgp has been demonstrated to
have an extended half-life, did not show any resistance to
DOX. While this observation may be fortuitous, a relation-
ship may exist between factors that regulate Pgp stability and
the drug resistance profile expressed.
The increased resistance of these DXR-10/VCR cells to
DOX may also involve other mechanisms either in associa-
tion with or independent of Pgp overexpression. Modified
glutathione levels and expression of glutathione-related enz-
ymes and certain antioxidant enzymes such as catalase and
superoxide dismutase have been implicated in certain DOX-
resistant MDR sublines, but this is not a universal finding, as
discussed recently (Hosking et al., 1990; McClean et al.,
1993b). However, our report that none of these parameters
was altered significantly in the drug-selected CHRC5 subline,
which expressed resistance to DOX and was derived from the
same AuxBl parental cells used in this present study, sug-
gests that they are unlikely to play a significant role in
influencing ADR cytotoxicity in these CHO sublines.
In summary, characterisation of a newly derived subline
selected for resistance by X-ray and then VCR exposures
provides further information on the expression of multiple
drug resistance following X-ray pretreatment. These data
show that the effect of further drug selection was additive to
the expression of multiple drug resistance resulting from the
initial X-ray treatment. However, it appears that subsequent
drug selection resulted in an additional 'classical' MDR-like
phenotype (including elevations in Pgp mRNA, reduced Pgp
half-life and resistance to DOX) rather than merely enhancing
expression of the specific novel phenotype identified follow-
ing fractionated X-irradiation pretreatment. These observati-
ons, ifconfirmed in similarly derived human tumour sublines,
may have some relevance in designing clinical combined
modality therapies, although radiation could alter subsequent
chemotherapy response via other pathways, such as damage
to tumour vasculature altering drug delivery.
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